Evolus (NASDAQ:EOLS) Releases Earnings Results, Misses Expectations By $0.02 EPS

Evolus (NASDAQ:EOLS) issued its quarterly earnings results on Monday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), FiscalAI reports. The firm had revenue of $73.14 million during the quarter, compared to the consensus estimate of $72.52 million.

Evolus Trading Up 4.7%

NASDAQ:EOLS traded up $0.25 on Monday, hitting $5.58. The company’s stock had a trading volume of 2,070,149 shares, compared to its average volume of 1,165,202. The stock has a fifty day moving average of $4.68 and a two-hundred day moving average of $5.63. The firm has a market capitalization of $363.03 million, a P/E ratio of -6.89 and a beta of 1.28. Evolus has a one year low of $3.86 and a one year high of $12.24.

Insider Activity

In other news, insider David Moatazedi sold 116,720 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $570,760.80. Following the transaction, the insider directly owned 618,369 shares of the company’s stock, valued at $3,023,824.41. This represents a 15.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rui Avelar sold 29,996 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $146,680.44. Following the completion of the transaction, the insider directly owned 430,542 shares in the company, valued at $2,105,350.38. The trade was a 6.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 163,504 shares of company stock worth $797,184 over the last three months. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Evolus

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. bought a new stake in shares of Evolus in the 4th quarter valued at about $34,000. Wexford Capital LP bought a new stake in shares of Evolus in the 3rd quarter valued at $37,000. Aquatic Capital Management LLC bought a new stake in shares of Evolus in the 3rd quarter valued at $48,000. State of Wyoming bought a new stake in shares of Evolus in the 4th quarter valued at $63,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after purchasing an additional 5,691 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on EOLS shares. Mizuho set a $15.00 target price on Evolus in a report on Wednesday, February 4th. Stifel Nicolaus dropped their target price on Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. BTIG Research reiterated a “buy” rating and set a $13.00 target price on shares of Evolus in a report on Wednesday, March 4th. Wall Street Zen lowered Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Weiss Ratings lowered shares of Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Evolus presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.